{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:42Z","timestamp":1791357402017,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011520","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000}}],"reference-count":125,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011520.pub2","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T11:24:30Z","timestamp":1499253870000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Vortioxetine for depression in adults"],"prefix":"10.1002","volume":"2017","author":[{"given":"Markus","family":"Koesters","sequence":"first","affiliation":[{"name":"Ulm University; Department of Psychiatry II; Ludwig-Heilmeyer-Str. 2 Guenzburg Germany D-89312"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ostuzzi","sequence":"additional","affiliation":[{"name":"University of Verona; \u200bDepartment of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry; Policlinico \"GB Rossi\" Piazzale L.A. Scuro, 10 Verona Italy 37134"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Guaiana","sequence":"additional","affiliation":[{"name":"Western University; Department of Psychiatry; Saint Thomas Elgin General Hospital 189 Elm Street St Thomas ON Canada N5R 5C4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Breilmann","sequence":"additional","affiliation":[{"name":"Ulm University; Department of Psychiatry II; Ludwig-Heilmeyer-Str. 2 Guenzburg Germany D-89312"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[{"name":"University of Verona; Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry; Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD011520.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S1461145711001027","article-title":"A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder","volume":"15","author":"Alvarez","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0002|cit2","unstructured":"NCT00839423 Randomised placebo-controlled venlafaxine-referenced study of efficacy and safety of 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in adults clinicaltrials.gov\/ct2\/show\/NCT00839423"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011520.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/S0924-977X(11)70627-7","article-title":"A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in MDD treatment","volume":"21","author":"Baldwin","year":"2011","journal-title":"European Neuropsychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD011520.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","article-title":"A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)","volume":"22","author":"Baldwin","year":"2012","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0005|cit5","unstructured":"NCT00635219 Randomised placebo-controlled duloxetine-referenced efficacy and safety study of 2.5, 5 and 10 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder clinicaltrials.gov\/ct2\/show\/NCT00635219"},{"issue":"3","key":"10.1002\/14651858.CD011520.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","article-title":"Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg\/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder","volume":"29","author":"Boulenger","year":"2014","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0007|cit7","unstructured":"NCT01140906 A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg\/day) in the acute treatment of adult patients with major depressive disorder clinicaltrials.gov\/show\/NCT01140906"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011520.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S393","DOI":"10.1016\/S0924-977X(11)70632-0","article-title":"Efficacy and tolerability of multiple doses of LU AA21004 in an 8-week trial of adults with major depressive disorder","volume":"21","author":"Henigsberg","year":"2011","journal-title":"European Neuropsychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD011520.pub2-BIB0009|cit9","first-page":"953","article-title":"A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder","volume":"73","author":"Henigsberg","year":"2012","journal-title":"Journal of Clinical Psychology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0010|cit10","unstructured":"NCT00707980 A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder clinicaltrials.gov\/ct2\/show\/NCT00707980"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0011|cit11","unstructured":"NCT00735709 A randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study comparing the efficacy and safety of 3 doses of Lu AA21004 in acute treatment of adults with major depressive disorder clinicaltrials.gov\/show\/NCT00735709"},{"issue":"5","key":"10.1002\/14651858.CD011520.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.14m09335","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder","volume":"76","author":"Jacobsen","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0013|cit13","unstructured":"NCT01163266 A phase 3, randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study comparing the efficacy and safety of 2 doses (10 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder clinicaltrials.gov\/show\/NCT01163266"},{"issue":"2","key":"10.1002\/14651858.CD011520.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S1461145712000727","article-title":"A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder","volume":"16","author":"Jain","year":"2013","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0015|cit15","unstructured":"NCT00672958 A randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study comparing the efficacy and safety of Lu AA21004 versus placebo in acute treatment of adults with major depressive disorder clinicaltrials.gov\/show\/NCT00672958"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1016\/S0924-977X(12)70388-7","article-title":"A randomised, double-blind, placebo controlled, active-referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients","volume":"22","author":"Katona","year":"2012","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011520.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0018|cit18","unstructured":"NCT00811252 Randomised placebo-controlled duloxetine-referenced study of efficacy and safety of 5 mg of vortioxetine (Lu AA21004) in acute treatment of major depressive disorder in elderly patients clinicaltrials.gov\/ct2\/show\/NCT00811252"},{"issue":"3","key":"10.1002\/14651858.CD011520.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1185\/03007995.2012.761600","article-title":"A randomized, double-blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder","volume":"29","author":"Mahableshwarkar","year":"2013","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0020|cit20","unstructured":"NCT00672620 A randomized, double-blind, parallel-group, placebo-controlled, active-referenced, fixed-dose study comparing the efficacy and safety of 2 doses of Lu AA21004 in acute treatment of adults with major depressive disorder clinicaltrials.gov\/show\/NCT00672620"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0021|cit21","unstructured":"NCT00707980 A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 in subjects with major depressive disorder clinicaltrials.gov\/ct2\/show\/NCT00707980"},{"issue":"12","key":"10.1002\/14651858.CD011520.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00213-014-3839-0","article-title":"A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD","volume":"232","author":"Mahableshwarkar","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0023|cit23","unstructured":"NCT01153009 A phase 3, randomized, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of 2 doses (15 and 20 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder clinicaltrials.gov\/show\/NCT01153009"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0024|cit24","unstructured":"Jacobson W Harvey P Merikle E Zhong W Nomikos G Olsen CK Impact of vortioxetine on functional capacity in MDD patients with subjective cognitive dysfunction: performance on the University of California San Diego performance-based skills assessment (UPSA) 54th Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2015 Dec 6-10; Hollywood (FL) 2015 S150 1"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Jacobson W Olsen C Mahableshwarkar A Yinzhong C Keefe R Effect of vortioxetine on functional capacity in patients with major depressive disorder with self-reported cognitive dysfunction 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug - 1 Sept; Amsterdam Netherlands 2015 S460","DOI":"10.1016\/S0924-977X(15)30622-2"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0026|cit26","first-page":"S389","article-title":"Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double-blind, duloxetine-referenced, placebo-controlled","volume":"39","author":"Keefe","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD011520.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/npp.2015.52","article-title":"A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder","volume":"40","author":"Mahableshwarkar","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0028|cit28","unstructured":"NCT01564862 A randomized, double-blind, parallel-group, placebo-controlled, active-referenced, flexible dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult subjects with major depressive disorder (MDD) clinicaltrials.gov\/show\/NCT01564862"},{"issue":"5","key":"10.1002\/14651858.CD011520.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4088\/JCP.14m09337","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder","volume":"76","author":"Mahableshwarkar","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0030|cit30","unstructured":"NCT01179516 A phase 3, randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study comparing the efficacy and safety of 2 doses (10 and 15 mg) of Lu AA21004 in acute treatment of adults with major depressive disorder clinicaltrials.gov\/show\/NCT01179516"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Harrison J Assessment of cognitive dysfunction in patients with depression - which test is best? 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug - 1 Sept; Amsterdam Netherlands 2015 S669","DOI":"10.1016\/S0924-977X(15)30957-3"},{"issue":"10","key":"10.1002\/14651858.CD011520.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1017\/S1461145714000546","article-title":"A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults","volume":"17","author":"McIntyre","year":"2014","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0033|cit33","unstructured":"McIntyre RS Lophaven S Olsen CK Randomized, double-blind, placebo-controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD) 52nd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2013 Dec 8-12; Hollywood (FL) 2013 S380 1"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0034|cit34","unstructured":"NCT01422213 Randomised, double-blind, parallel-group, placebo-controlled, fixed dose study on the efficacy of [vortioxetine] Lu AA21004 on cognitive dysfunction in adult patients with major depressive disorder (MDD) clinicaltrials.gov\/show\/NCT01422213"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0035|cit35","unstructured":"Euctr2010-022257-41-Lv A multinational, randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder - efficacy and safety of Lu AA21004 for treatment of major depressive disorder www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2010-022257-41 2010"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0036|cit36","unstructured":"NCT01255787 A multinational, randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder clinicaltrials.gov\/show\/NCT01255787"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0037|cit37","unstructured":"Jprn-Japiccti-111492 A randomized, double-blind, placebo-controlled, phase III study to assess the efficacy and safety of LuAA21004 in patients with major depressive disorder www.clinicaltrials.jp\/user\/showCteDetailE.jsp?japicId=JapicCTI-111492"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0038|cit38","unstructured":"NCT01355081 A randomized, double-blind, placebo-controlled, parallel-group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder clinicaltrials.gov\/show\/NCT01355081"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0039|cit39","unstructured":"Kct0000432 Randomised, double-blind, parallel-group, active-comparator (venlafaxine extended release), fixed-dose study of LuAA21004 in major depressive disorder in Asian countries cris.nih.go.kr\/cris\/en\/search\/search_result_st01.jsp?seq=2532"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0040|cit40","unstructured":"NCT01571453 Randomised, double-blind, parallel-group, active-comparator (venlafaxine extended release), fixed-dose study of [vortioxetine] Lu AA21004 in major depressive disorder in Asian countries clinicaltrials.gov\/show\/NCT01571453"},{"issue":"4","key":"10.1002\/14651858.CD011520.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1185\/03007995.2015.1014028","article-title":"Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study","volume":"31","author":"Wang","year":"2015","journal-title":"Current Medical Research and Opinion"},{"issue":"11","key":"10.1002\/14651858.CD011520.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1177\/0269881112441866","article-title":"A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder","volume":"26","author":"Boulenger","year":"2012","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0043|cit43","unstructured":"NCT00596817 Efficacy of Lu AA21004 in the prevention of relapse of major depressive episodes clinicaltrials.gov\/ct2\/show\/NCT00596817"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Browning M Smith J Conen S Smallman R Buchbjerg J Larsen Kg Vortioxetine reduces BOLD signal during performance of the N-back task in subjects remitted from depression and healthy control participants 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands 2015 S314 5","DOI":"10.1016\/S0924-977X(15)30385-0"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0045|cit45","unstructured":"Browning M Smith J Conen S Smallman R Buchbjerg J Larsen Kg Vortioxetine reduces bold signal during performance of the N-Back task in subjects remitted from depression and healthy control participants [abstract] 53rd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2014 Dec 7-11; Phoenix (AZ) 2014 S480"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Conen S McKie S Smallman RP Dutta A Dawson Gr Smith J Effects of vortioxetine on resting-state activity in subjects remitted from depression and healthy controls 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands 2015 S442","DOI":"10.1016\/S0924-977X(15)30593-9"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0047|cit47","unstructured":"Dawson G Conen S McKie S Smallman R Smith J Browning M Effects of vortioxetine on resting-state activity in subjects remitted from depression and healthy controls 53rd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2014 Dec 7-11; Phoenix (AZ) 2014 S214 5"},{"issue":"10","key":"10.1002\/14651858.CD011520.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/jsm.12980","article-title":"Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction","volume":"12","author":"Jacobsen","year":"2015","journal-title":"Journal of Sexual Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011520.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/YIC.0000000000000081","article-title":"Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study","volume":"30","author":"Jacobsen","year":"2015","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0050|cit50","doi-asserted-by":"crossref","unstructured":"Haggstrom L Nielsen RZ Danchenko N Poulsen L A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI\/SNRI treatment 26th European College of Neuropsychopharmacology, ECNP Congress; 2013 Oct 5-9; Barcelona, Spain 2013 S412","DOI":"10.1016\/S0924-977X(13)70652-7"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011520.pub2-BIB0051|cit51","first-page":"3009","article-title":"Randomized, double-blind, study of vortioxetine versus agomelatine in adults with MDD after inadequate response to SSRI or SNRI treatment","volume":"28","author":"Haggstrom","year":"2013","journal-title":"European Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011520.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hup.2424","article-title":"A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine","volume":"29","author":"Montgomery","year":"2014","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0053|cit53","unstructured":"NCT01488071 A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder with inadequate response to antidepressant treatment clinicaltrials.gov\/show\/NCT01488071"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/S0924-977X(14)70745-X","article-title":"Efficacy and tolerability of vortioxetine is independent of previous treatment in MDD patients switched after an inadequate response","volume":"24","author":"Papakostas","year":"2014","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0055|cit55","unstructured":"NCT02371980 A randomized, double-blind, placebo-controlled, phase 4, relapse prevention study evaluating the efficacy and safety of vortioxetine (5, 10 and 20 mg) in adults with major depressive disorder clinicaltrials.gov\/show\/NCT02371980"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0056|cit56","unstructured":"NCT02272517 An interventional, randomised, double-blind, parallel-group, active-comparator, flexible-dose study on the efficacy of vortioxetine versus escitalopram on cognitive dysfunction in patients with inadequate response to current antidepressant treatment of major depressive disorder clinicaltrials.gov\/show\/NCT02272517"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0057|cit57","unstructured":"NCT02279966 An interventional, randomised, double-blind, parallel-group, placebo-controlled, active-referenced (paroxetine), fixed-dose study on the efficacy of vortioxetine on cognitive dysfunction in working patients with major depressive disorder clinicaltrials.gov\/show\/NCT02279966"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0058|cit58","unstructured":"NCT02294305 Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder clinicaltrials.gov\/show\/NCT02294305"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0059|cit59","unstructured":"Jprn-Japiccti-152831 A randomized, double-blind, placebo-controlled, parallel-group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder www.clinicaltrials.jp\/user\/showCteDetailE.jsp?japicId=JapicCTI-152831"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0060|cit60","unstructured":"NCT02389816 A randomized, double-blind, placebo-controlled, parallel-group, phase III study to assess the efficacy and safety of Lu AA21004 in patients with major depressive disorder clinicaltrials.gov\/show\/NCT02389816"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0061|cit61","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-III)","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0062|cit62","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)","author":"American Psychiatric Association","year":"1987"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0063|cit63","article-title":".","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0064|cit64","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0065|cit65","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423387.654001","volume-title":"American Psychiatric Association Practice Guidelines for the Treatment of Patients with Major Depressive Disorder","author":"American Psychiatric Association","year":"2010"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0066|cit66","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"issue":"3","key":"10.1002\/14651858.CD011520.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/0269881116628440","article-title":"The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"2","key":"10.1002\/14651858.CD011520.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01.jcp.0000115665.45074.0d","article-title":"\"Wish bias\" in antidepressant drug trials?","volume":"24","author":"Barbui","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011520.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.eurpsy.2007.11.001","article-title":"Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study","volume":"23","author":"Bauer","year":"2008","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12888-014-0276-x","article-title":"Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials","volume":"14","author":"Berhan","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1741-7015-9-90","article-title":"Cross-national epidemiology of DSM-IV major depressive episode","volume":"9","author":"Bromet","year":"2011","journal-title":"BMC Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011520.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1345\/aph.1A254","article-title":"Discontinuing or switching selective serotonin-reuptake inhibitors","volume":"36","author":"Bull","year":"2002","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0073|cit73","unstructured":"Center for Drug Evaluation and Research Application number: 204447Orig1s000. Medical review(s), 2013 www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204447orig1s000medr.pdf"},{"issue":"344","key":"10.1002\/14651858.CD011520.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"d8013","DOI":"10.1136\/bmj.d8013","article-title":"Out of sight but not out of mind: how to search for unpublished clinical trial evidence","volume":"3","author":"Chan","year":"2012","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0075|cit75","unstructured":"Chinese Society of Psychiatry The Chinese Classification and Diagnostic Criteria of Mental Disorders Version 3 (CCMD-3) 2001 www.21jk.com.cn\/english\/"},{"issue":"9665","key":"10.1002\/14651858.CD011520.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011520.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/ijcp.12350","article-title":"Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"68","author":"Citrome","year":"2014","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jad.2016.02.042","article-title":"Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"196","author":"Citrome","year":"2016","journal-title":"Journal of Affective Disorders"},{"issue":"14","key":"10.1002\/14651858.CD011520.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1007\/s00213-016-4327-5","article-title":"Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression","volume":"233","author":"Du Jardin","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0080|cit80","unstructured":"European Medical Agency Brintellix: EPAR-Summary for the public http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002717\/WC500159448.pdf"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0081|cit81","unstructured":"European Medicines Agency Brintellix EPAR - public assessment report 2014 www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002717\/WC500159447.pdf"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0082|cit82","unstructured":"European Medicines Agency Brintellix: EPAR - product information 2014 www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002717\/WC500159449.pdf"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0083|cit83","unstructured":"Us. Food Drug Administration Novel New Drugs 2013 Summary https:\/\/www.fda.gov\/downloads\/drugs\/developmentapprovalprocess\/druginnovation\/ucm381803.pdf"},{"issue":"1","key":"10.1002\/14651858.CD011520.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archpsyc.1972.01750190059011","article-title":"Diagnostic criteria for use in psychiatric research","volume":"26","author":"Feighner","year":"1972","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0085|cit85","doi-asserted-by":"crossref","unstructured":"Florea I Loft H Danchenko N Rive B Brignone M Merikle E Vortioxetine effects on overall patient functioning in patients with major depressive disorder 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands 2015 S436","DOI":"10.1016\/S0924-977X(15)30584-8"},{"issue":"1","key":"10.1002\/14651858.CD011520.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00213-014-3633-z","article-title":"The efficacy and safety of 5 mg\/d Vortioxetine compared to placebo for major depressive disorder: a meta-analysis","volume":"232","author":"Fu","year":"2015","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011520.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ije\/31.1.72","article-title":"Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD011520.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analyses","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011520.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD011520.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"772","DOI":"10.7326\/0003-4819-155-11-201112060-00009","article-title":"Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis","volume":"155","author":"Gartlehner","year":"2011","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011520.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11920-012-0283-x","article-title":"How should primary care doctors select which antidepressants to administer?","volume":"14","author":"Gartlehner","year":"2012","journal-title":"Current Psychiatry Reports"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0092|cit92","unstructured":"GRADE Working Group, McMaster University GRADEpro 2014"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0093|cit93","first-page":"f7450","article-title":"Converting an odds ratio to a range of plausible relative risks for better communication of research findings","volume":"348","author":"Grant","year":"2014","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD011520.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/0019-5545.105503","article-title":"IPS multicentric study: antidepressant prescription patterns","volume":"55","author":"Grover","year":"2013","journal-title":"Indian Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD011520.pub2-BIB0095|cit95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008851.pub2","article-title":"Agomelatine versus other antidepressive agents for major depression","author":"Guaiana","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0096|cit96","volume-title":"Manual for the ECDEU Assessment Battery 2","author":"Guy","year":"1970"},{"issue":"7132","key":"10.1002\/14651858.CD011520.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/bmj.316.7132.690","article-title":"Interpreting treatment effects in randomised trials","volume":"316","author":"Guyatt","year":"1998","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD011520.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence - imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0100|cit100","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD011520.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011520.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1192\/bjp.bp.112.120196","article-title":"Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials","volume":"203","author":"Koesters","year":"2013","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/2046-4053-2-81","article-title":"Assessing and presenting summaries of evidence in Cochrane Reviews","volume":"2","author":"Langendam","year":"2013","journal-title":"Systematic Reviews"},{"issue":"2-3","key":"10.1002\/14651858.CD011520.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jad.2012.12.001","article-title":"What does the HAMD mean?","volume":"148","author":"Leucht","year":"2013","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0105|cit105","first-page":"523","article-title":"The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials","volume":"12","author":"Li","year":"2016","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13643-015-0001-y","article-title":"The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis","volume":"4","author":"Meeker","year":"2015","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011520.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YIC.0b013e32832a8eb2","article-title":"Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?","volume":"24","author":"Montgomery","year":"2009","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0109|cit109","volume-title":"Depression in Adults. CG90","author":"National Institute for Health and Care Excellence","year":"2009"},{"issue":"2","key":"10.1002\/14651858.CD011520.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1017\/S1092852915000486","article-title":"Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission","volume":"21","author":"Pehrson","year":"2016","journal-title":"CNS Spectrums"},{"issue":"1","key":"10.1002\/14651858.CD011520.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1891\/1559-4343.13.1.6","article-title":"STAR*D: a tale and trail of bias","volume":"13","author":"Pigott","year":"2011","journal-title":"Ethical Human Psychology and Psychiatry"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0112|cit112","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"4","key":"10.1002\/14651858.CD011520.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mpr.320","article-title":"Evaluation of the DSM-IV and ICD-10 criteria for depressive disorders in a community population in Japan using item response theory","volume":"19","author":"Saito","year":"2010","journal-title":"International Journal of Methods in Psychiatric Research"},{"issue":"4","key":"10.1002\/14651858.CD011520.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0447.2010.01599.x","article-title":"A systematic review of duloxetine and venlafaxine in major depression, including unpublished data","volume":"123","author":"Schueler","year":"2011","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0115|cit115","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A editor(s) GRADE handbook. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. [updated October 2013]. The GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"6","key":"10.1002\/14651858.CD011520.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archpsyc.1978.01770300115013","article-title":"Research diagnostic criteria: rationale and reliability","volume":"35","author":"Spitzer","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011520.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1017\/S1092852915000346","article-title":"Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine","volume":"20","author":"Stahl","year":"2015","journal-title":"CNS Spectrums"},{"issue":"6","key":"10.1002\/14651858.CD011520.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.euroneuro.2016.03.007","article-title":"A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults","volume":"26","author":"Thase","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0119|cit119","unstructured":"Vos T Flaxman AD Naghavi M Lozano R Michaud C Ezzati M Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 2012 2163 96"},{"issue":"4","key":"10.1002\/14651858.CD011520.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00213-007-0975-9","article-title":"Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis","volume":"196","author":"Weinmann","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0121|cit121","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders","author":"World Health Organization (WHO)","year":"1992"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0122|cit122","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology ATC\/DDD Index 2017 https:\/\/www.whocc.no\/atc_ddd_index\/?code=N06AX26"},{"issue":"4","key":"10.1002\/14651858.CD011520.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/appy.12022","article-title":"Preliminary study of patterns of medication use for depression treatment in China","volume":"5","author":"Zhang","year":"2013","journal-title":"Asia-Pacific Psychiatry: Official Journal of the Pacific Rim College of Psychiatrists"},{"issue":"1","key":"10.1002\/14651858.CD011520.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.14r09164","article-title":"The US Food and Drug Administration's perspective on the new antidepressant vortioxetine","volume":"76","author":"Zhang","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011520.pub2-BIB0125|cit125","first-page":"f7668","article-title":"Quality of reporting in systematic reviews of adverse events: systematic review","volume":"348","author":"Zorzela","year":"2014","journal-title":"BMJ (Clinical Research Ed.)"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD011520.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T15:49:16Z","timestamp":1626623356000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011520.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":125,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011520.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,5]]}}}